Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22914583 | 0.82 | NOS2 (0.37) | BACE1CYP2A6ASIC3LOXL2SMN1; SMN2 | |
| SCHEMBL24601455 | 0.81 | CYP2A6 (0.58) | BACE1CYP2A6ASIC3LOXL2SMN1; SMN2 | |
| SCHEMBL6253354 | 0.80 | CYP2A6 (0.55) | BACE1CYP2A6ASIC3LOXL2SMN1; SMN2 | |
| SCHEMBL6958993 | 0.78 | CYP2A6 (0.50) | CYP2A6ASIC3LOXL2ADRB2RAB9A | |
| SCHEMBL10222545 | 0.78 | CYP2A6 (0.45) | BACE1CYP2A6ASIC3LOXL2SMN1; SMN2 | |
| SCHEMBL13495923 | 0.77 | BACE1 (0.57) | BACE1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL13791093 | 0.77 | DYRK1A (0.51) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL2056139 | 0.77 | AKR1B1 (0.39) | CYP2A6ASIC3LOXL2SMN1; SMN2ADRB2 | |
| SCHEMBL9980132 | 0.77 | MAPK1 (0.39) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL10163618 | 0.74 | GRIN2C (0.40) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4085059-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE HK LTD (HK) | 2024-03-20 | — | — | EP | disclosed |
| EP-4085059-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE HK LTD (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2023-04-20 | — | — | US | disclosed |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2023-04-20 | — | — | US | disclosed |
| EP-4085059-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | Accro Bioscience (HK) Limited (HK) | 2022-11-09 | — | — | EP | disclosed |
| WO-2021138694-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138694-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | BACE1 190/4885CYP2A6 162/4885ASIC3 1996/4885 |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | BAX, PDCD1, PDCD4 | BACE1 380/4885CYP2A6 1469/4885ASIC3 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.